TTY Biopharm - Public Comps and Valuation Multiples

TTY Biopharm Overview

About TTY Biopharm

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

Founded

1960

HQ

Employees

561

Website

tty.com.tw

Sectors

Drug Development & Therapeutics
Contract Research & Manufacturing
BioTech

Financials

LTM Revenue $205M

LTM EBITDA $1.0M

EV

$623M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

TTY Biopharm Financials

As of November 2025, TTY Biopharm reported last 12-month revenue of $205M and EBITDA of $1.0M.

In the same period, TTY Biopharm generated $126M in LTM gross profit and $53.0M in net income.

See TTY Biopharm valuation multiples based on analyst estimates

TTY Biopharm P&L

In the most recent fiscal year, TTY Biopharm reported revenue of $188M and EBITDA of $67.7M.

TTY Biopharm expects next 12-month revenue of XXX and NTM EBITDA of XXX

See TTY Biopharm valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$205M	XXX	$188M	XXX	XXX	XXX
Gross Profit	$126M	XXX	$109M	XXX	XXX	XXX
Gross Margin	62%	XXX	58%	XXX	XXX	XXX
EBITDA	$1.0M	XXX	$67.7M	XXX	XXX	XXX
EBITDA Margin	0%	XXX	36%	XXX	XXX	XXX
EBIT	$58.3M	XXX	$44.4M	XXX	XXX	XXX
EBIT Margin	28%	XXX	24%	XXX	XXX	XXX
Net Profit	$53.0M	XXX	$46.2M	XXX	XXX	XXX
Net Margin	26%	XXX	25%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for TTY Biopharm including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $205M. EBITDA for the last twelve months was $1.0M. In the most recent fiscal year, TTY Biopharm achieved $188M in revenue and $67.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$205M	Analyst estimates available to subscribers	$188M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$126M	Analyst estimates available to subscribers	$109M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	61.5% gross margin	Analyst estimates available to subscribers	57.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$1.0M	Analyst estimates available to subscribers	$67.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	0.5% EBITDA margin	Analyst estimates available to subscribers	36.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$58.3M	Analyst estimates available to subscribers	$44.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	28.4% EBIT margin	Analyst estimates available to subscribers	23.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$53.0M	Analyst estimates available to subscribers	$46.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	25.8% net profit margin	Analyst estimates available to subscribers	24.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for TTY Biopharm

This financial data table provides comprehensive performance metrics for TTY Biopharm, a company based in Taiwan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

TTY Biopharm generated $205M in revenue over the last twelve months.
The company achieved $1.0M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $126M.
Net income over the last twelve months reached $53.0M.

Fiscal Year Performance

In the most recent fiscal year, TTY Biopharm reported $188M in total revenue.
Fiscal year EBITDA was $67.7M.
The company maintained a gross profit margin of 57.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 36.1%.
Net profit margin reached 24.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for TTY Biopharm. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

TTY Biopharm Stock Performance

TTY Biopharm has current market cap of TWD 20.6B (or $656M), and EV of TWD 19.6B (or $623M).

Market Cap Evolution

TTY Biopharm Stock Data

As of December 3, 2025, TTY Biopharm's stock price is TWD 83 (or $3).

See TTY Biopharm trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$623M	$656M	XXX	XXX	XXX	XXX	$0.21

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

TTY Biopharm Valuation Multiples

TTY Biopharm's trades at 3.3x EV/Revenue multiple, and 9.2x EV/EBITDA.

See valuation multiples for TTY Biopharm and 15K+ public comps

TTY Biopharm Financial Valuation Multiples

As of December 3, 2025, TTY Biopharm has market cap of $656M and EV of $623M.

Equity research analysts estimate TTY Biopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

TTY Biopharm has a P/E ratio of 12.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$656M	XXX	$656M	XXX	XXX	XXX
EV (current)	$623M	XXX	$623M	XXX	XXX	XXX
EV/Revenue	3.0x	XXX	3.3x	XXX	XXX	XXX
EV/EBITDA	611.7x	XXX	9.2x	XXX	XXX	XXX
EV/EBIT	10.7x	XXX	14.0x	XXX	XXX	XXX
EV/Gross Profit	4.9x	XXX	n/a	XXX	XXX	XXX
P/E	12.4x	XXX	14.2x	XXX	XXX	XXX
EV/FCF	15.9x	XXX	16.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TTY Biopharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

TTY Biopharm Margins & Growth Rates

TTY Biopharm's last 12 month revenue growth is 10%

TTY Biopharm's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

TTY Biopharm's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TTY Biopharm's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for TTY Biopharm and other 15K+ public comps

TTY Biopharm Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	10%	XXX	10%	XXX	XXX	XXX
EBITDA Margin	0%	XXX	36%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	40%	XXX	46%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	26%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	22%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	34%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial